Lupin Ltd Reports Record Rs 27,958 Cr Revenue in FY2026; FY2027 Margins Expected Around 25%

Lupin Ltd has reported a record-breaking fiscal year 2026, with total revenues climbing to Rs 27,958 crores. The company achieved strong EBITDA margins of 29.7% for the year, though it anticipates these margins will moderate to around 25% in FY2027.

Strong U.S. Growth Fuels Record Revenue

A significant driver of this performance was the company's U.S. business, which saw a robust 40% year-on-year increase in sales, reaching USD 1.3 billion. Key products such as Tolvaptan, Mirabegron, and Risperdal Consta contributed strongly to this growth.

India Performance Outpaces Market

In India, Lupin's core prescription business expanded by 14.5% in the fourth quarter of FY2026, outpacing the broader Indian Pharmaceutical Market (IPM) growth of 11.6% for the same period.

Operational Gains and Regulatory Updates

Operationally, the company reported strong Q4 FY2026 gross margins of 75%. Its working capital cycle improved to 87 days from 110 days in the prior year. Additionally, Lupin's Goa manufacturing facility received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (USFDA).

Strategic Strengths and Future Outlook

This record performance builds on strategic moves, including the July 2023 acquisition of Italy-based VISUfarma, which has boosted Lupin's European presence in markets like Italy and Spain and strengthened its ophthalmology offerings. The positive U.S. growth highlights the company's market penetration. However, management's guidance for FY2027, projecting margins around 25% compared to the current 29.7%, signals a necessary adjustment. This moderation is expected due to increasing competition and rising operational costs.

Investor Takeaways and Key Challenges

For shareholders, FY2026 marks a successful execution phase. The outlook for FY2027 shifts focus to managing heightened competition and cost pressures, including significant increases in freight rates (ocean up 15%, air up 60% due to geopolitical factors). The company aims to sustain its U.S. revenue stream, which exceeded USD 1.3 billion, even as key products like Tolvaptan face generic competition following its patent expiry around September. Lupin is also working to overcome manufacturing ramp-up challenges at contract manufacturers impacting supply for products like Risperdal Consta. The successful integration of VISUfarma remains crucial for expanding European sales.

Comparison with Peers

Lupin operates in a competitive landscape. Sun Pharma, another U.S. generics leader, benefits from a diversified portfolio including specialty drugs that could offer different margin protection. Dr. Reddy's Laboratories also navigates U.S. generics and biosimilars, emphasizing R&D and complex product development. Cipla faces similar U.S. market challenges and is building its specialty segment while managing generic competition.

Key Financial Metrics

Key figures from FY2026 include consolidated revenue of Rs 27,958 crores and an EBITDA margin of 29.7%. The working capital cycle improved to 87 days. U.S. sales reached USD 1.3 billion. For FY2027, the company has guided for EBITDA margins of approximately 25%.

What to Watch Next

Lupin's performance against its FY2027 revenue growth and EBITDA margin guidance. Successful launch and market uptake of new products such as Ravicti, Pegfilgrastim, and Semaglutide. The competitive impact following the Tolvaptan patent expiry and market entries. Performance and integration progress of the VISUfarma acquisition in expanding European sales. Management's effectiveness in addressing manufacturing and supply chain constraints for key products. Any further updates regarding U.S. facility compliance.